Literature DB >> 24944409

Treatment of complex regional pain syndrome type 1 in a pediatric patient using the lidocaine patch 5%: a case report.

Steven G Frost1.   

Abstract

BACKGROUND: Successful treatment of complex regional pain syndrome type 1 (CRPS-1) requires a coordinated, multidisciplinary approach. Physical rehabilitation is an important component of long-term treatment. Unfortunately, patients with significant allodynia or hyperalgesia characteristic of CRPS-1 often have difficulty progressing through a physical therapy (PT) regimen. In most adults with CRPS-1, the treatment of choice is PO opioids.
OBJECTIVE: This article presents a case report of the use of the lidocaine patch 5%, a targeted peripheral analgesic, in a pediatric patient and its effects on reducing pain, improving the patient's overall attitude, and facilitating compliance with ongoing PT.
RESULTS: A 10-year-old girl developed CRPS-1 after arthroscopic surgery for a sprained ankle. Attempts at PT were unsuccessful due to inadequate pain relief from various treatment modalities. Therapy with the lidocaine patch 5% was initiated and resulted in significant pain relief, improvements in the patient's attitude, and progress with PT.
CONCLUSION: This case report of a child with CRPS-1 showed that therapy with lidocaine patch 5% may be efficacious in treating children with pain resulting from CRPS-1, thereby increasing the success of PT.

Entities:  

Keywords:  complex regional pain syndrome; lidocaine patch 5%; pediatrics; targeted peripheral analgesic

Year:  2003        PMID: 24944409      PMCID: PMC4053049          DOI: 10.1016/j.curtheres.2003.09.010

Source DB:  PubMed          Journal:  Curr Ther Res Clin Exp        ISSN: 0011-393X


  2 in total

1.  Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study.

Authors:  A Devers; B S Galer
Journal:  Clin J Pain       Date:  2000-09       Impact factor: 3.442

Review 2.  Complex Regional Pain Syndromes: guidelines for therapy.

Authors:  M Stanton-Hicks; R Baron; R Boas; T Gordh; N Harden; N Hendler; M Koltzenburg; P Raj; R Wilder
Journal:  Clin J Pain       Date:  1998-06       Impact factor: 3.442

  2 in total
  7 in total

1.  Lidocaine 5%-medicated plaster (Versatis) for localised neuropathic pain: results of a multicentre evaluation of use in children and adolescents.

Authors:  John M Goddard; Rebecca L Reaney
Journal:  Br J Pain       Date:  2018-01-31

2.  5% Lidocaine-medicated plaster for the treatment of chronic peripheral neuropathic pain: complex regional pain syndrome and other neuropathic conditions.

Authors:  Enrique Calderón; María Eloísa Calderón-Seoane; Rafael García-Hernández; Luis Miguel Torres
Journal:  J Pain Res       Date:  2016-10-06       Impact factor: 3.133

Review 3.  Localized neuropathic pain: an expert consensus on local treatments.

Authors:  Gisèle Pickering; Elodie Martin; Florence Tiberghien; Claire Delorme; Gérard Mick
Journal:  Drug Des Devel Ther       Date:  2017-09-13       Impact factor: 4.162

4.  Recovery from acute pediatric complex regional pain syndrome type I after ankle sprain by early pharmacological and physical therapies in primary care: a case report.

Authors:  Yuzuru Takahashi; Takuya Tominaga; Kohei Okawa; Kohei Tanaka
Journal:  J Pain Res       Date:  2018-11-13       Impact factor: 3.133

Review 5.  Topical Lidocaine for Chronic Pain Treatment.

Authors:  Marion Voute; Véronique Morel; Gisèle Pickering
Journal:  Drug Des Devel Ther       Date:  2021-09-29       Impact factor: 4.162

6.  Can treatment success with 5% lidocaine medicated plaster be predicted in cancer pain with neuropathic components or trigeminal neuropathic pain?

Authors:  Kai-Uwe Kern; Srinivas Nalamachu; Louis Brasseur; Joanna M Zakrzewska
Journal:  J Pain Res       Date:  2013-04-05       Impact factor: 3.133

Review 7.  The Efficacy of Systemic Lidocaine in the Management of Chronic Pain: A Literature Review.

Authors:  Fardin Yousefshahi; Oana Predescu; Juan Francisco Asenjo
Journal:  Anesth Pain Med       Date:  2017-04-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.